Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 2/2012

01-06-2012 | Antiretroviral Therapies (A Pozniak, Section Editor)

HIV-1 Prevention for HIV-1 Serodiscordant Couples

Authors: Kathryn Curran, Jared M. Baeten, Thomas J. Coates, Ann Kurth, Nelly R. Mugo, Connie Celum

Published in: Current HIV/AIDS Reports | Issue 2/2012

Login to get access

Abstract

A substantial proportion of HIV-1 infected individuals in sub-Saharan Africa are in stable relationships with HIV-1 uninfected partners, and HIV-1 serodiscordant couples thus represent an important target population for HIV-1 prevention. Couple-based HIV-1 testing and counseling facilitates identification of HIV-1 serodiscordant couples, counseling about risk reduction, and referrals to HIV-1 treatment, reproductive health services, and support services. Maximizing HIV-1 prevention for HIV-1 serodiscordant couples requires a combination of strategies, including counseling about condoms, sexual risk, fertility, contraception, and the clinical and prevention benefits of antiretroviral therapy (ART) for the HIV-1-infected partner; provision of clinical care and ART for the HIV-1-infected partner; antenatal care and services to prevent mother-to-child transmission for HIV-1-infected pregnant women; male circumcision for HIV-1-uninfected men; and, pending guidelines and demonstration projects, oral pre-exposure prophylaxis (PrEP) for HIV-1-uninfected partners.
Literature
1.
2.
•• Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. This is the first randomized clinical trial to demonstrate that early initiation of ART (between CD4 350–550 cells/mL) significantly reduces the likelihood of transmitting HIV-1 to sexual partners. HIV-1 serodiscordant couples initiating ART early had 96% fewer HIV-1 infections and had lower incidence of tuberculosis..PubMedCrossRef
3.
•• Baeten J, Donnell D Ndase P, Mugo N, Mujugira A, Celum C, et al. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual men and women. CROI 2012, abstract 29. This randomized clinical trial demonstrated high efficacy of daily oral PrEP in preventing HIV-1 transmission in HIV-1 serodiscordant couples in sub-Saharan Africa: 67% with tenofovir and 75% with emtricitabine/tenofovir.
4.
Anand A, Shiraishi RW, Bunnell RE, et al. Knowledge of HIV status, sexual risk behaviors and contraceptive need among people living with HIV in Kenya and Malawi. AIDS. 2009;23(12):1565–73.PubMedCrossRef
5.
De Walque D. Sero-discordant couples in five African countries: implications for prevention strategies. Popul Dev Rev. 2007;33(3):501–23.CrossRef
6.
Kaiser R, Bunnell R, Hightower A, et al. Factors associated with HIV infection in married or cohabitating couples in Kenya: results from a nationally representative study. PLoS One. 2011;6(3):e17842.PubMedCrossRef
7.
Bunnell R, Opio A, Musinguzi J, et al. HIV transmission risk behavior among HIV-infected adults in Uganda: results of a nationally representative survey. AIDS. 2008;22(5):617–24.PubMedCrossRef
8.
Were WA, Mermin JH, Wamai N, et al. Undiagnosed HIV infection and couple HIV discordance among household members of HIV-infected people receiving antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr. 2006;43(1):91–5.PubMedCrossRef
9.
Lingappa JR, Lambdin B, Bukusi EA, et al. Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS One. 2008;3(1):e1411.PubMedCrossRef
10.
• Gray R, Ssempiija V, Shelton J, et al. The contribution of HIV-discordant relationships to new HIV infections in Rakai, Uganda. AIDS. 2011;25(6):863–5. This analysis of HIV-1 infections occurring in couples in a community cohort study in Uganda found that 18% and 13% of new infections are attributable to HIV-1 serodiscordant couples, pre and post ART respectively. This study used sequential population-based HIV-1 prevalence surveys..PubMedCrossRef
11.
12.
Coburn BJ, Gerberry DJ, Blower S. Quantification of the role of discordant couples in driving incidence of HIV in sub-Saharan Africa. Lancet Infect Dis. 2011;11(4):263–4.PubMedCrossRef
13.
Eyawo O, de Walque D, Ford N, et al. HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(11):770–7.PubMedCrossRef
14.
Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362(5):427–39.PubMedCrossRef
15.
Ndase P, Celum C, Thomas K, et al. Outside sexual partnerships and risk of HIV acquisition for HIV uninfected partners in African HIV serodiscordant partnerships. J Acquir Immune Defic Syndr. 2012;59(1):65–71.PubMedCrossRef
16.
17.
The World Health Organization: Guidance on Couples HIV Testing and Counselling and Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples: Recommendations for a public health approach. Release date 2012.
18.
The U.S. Centers for Disease Control and Prevention (CDC) Division of Global HIV and AIDS (DGHA): Couples HIV Testing and Counseling (CHTC) in Health Care Facilities Trainer’s Manual. Updated and adapted from CDC/DGHA Couples HIV Counseling and Testing Intervention and Training Curriculum (November 2009). In draft, November 2011.
19.
• Matovu JK. Preventing HIV transmission in married and cohabiting HIV-discordant couples in sub-Saharan Africa through combination prevention. Curr HIV Res. 2010;8(6):430–40. This review paper presents various HIV-1 prevention interventions, behavioral and biomedical, to include in a combination prevention intervention for HIV-1 serodiscordant couples in sub-Saharan Africa..PubMedCrossRef
20.
Allen S, Tice J, Van de Perre P, et al. Effect of serotesting with counselling on condom use and seroconversion among HIV discordant couples in Africa. Bmj. 1992;304(6842):1605–9.PubMedCrossRef
21.
The Voluntary HIV-1 Counseling and Testing Efficacy Study Group. Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomised trial. The Lancet. 2000;356(9224):103–12.CrossRef
22.
Kamenga M, Ryder RW, Jingu M, et al. Evidence of marked sexual behavior change associated with low HIV-1 seroconversion in 149 married couples with discordant HIV-1 serostatus: experience at an HIV counselling center in Zaire. AIDS 4091;5(1):61–7
23.
Allen S, Meinzen-Derr J, Kautzman M, et al. Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS. 2003;17(5):733–40.PubMedCrossRef
24.
Burton J, Darbes LA, Operario D. Couples-focused behavioral interventions for prevention of HIV: systematic review of the state of evidence. AIDS Behav. 2010;14(1):1–10.PubMedCrossRef
25.
Farquhar C, Kiarie JN, Richardson BA, et al. Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission. J Acquir Immune Defic Syndr. 2004;37(5):1620–6.PubMedCrossRef
26.
El-Bassel N, Gilbert L, Witte S, et al. Couple-based HIV prevention in the United States: advantages, gaps, and future directions. J Acquir Immune Defic Syndr. 2010;55 Suppl 2:S98–S101.PubMed
27.
Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357(9263):1149–53.PubMedCrossRef
28.
Ware NC, Idoko J, Kaaya S, et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med. 2009;6(1):e11.PubMedCrossRef
29.
Stirratt MJ, Remien RH, Smith A, et al. The role of HIV serostatus disclosure in antiretroviral medication adherence. AIDS and Behavior. 2006;10(5):483–93.PubMedCrossRef
30.
Were E, Wools-Kaloustian K, Baliddawa J, et al. Stakeholders perception of HIV sero-discordant couples in western Kenya. East Afr Med J. 2008;85(7):326–33.PubMed
31.
Bunnell RE, Nassozi J, Marum E, et al. Living with discordance: knowledge, challenges, and prevention strategies of HIV-discordant couples in Uganda. AIDS Care. 2005;17(8):999–1012.PubMedCrossRef
32.
Beyeza-Kashesya J, Kaharuza F, Mirembe F, et al. The dilemma of safe sex and having children: challenges facing HIV sero-discordant couples in Uganda. Afr Health Sci. 2009;9(1):2–12.PubMed
33.
Porter L, Hao L, Bishai D, et al. HIV status and union dissolution in sub-Saharan Africa: the case of Rakai, Uganda. Demography. 2004;41(3):465–82.PubMedCrossRef
34.
VanDevanter N, Thacker AS, Bass G, et al. Heterosexual couples confronting the challenges of HIV infection. AIDS Care. 1999;11(2):181–93.PubMedCrossRef
35.
Semrau K, Kuhn L, Vwalika C, et al. Women in couples antenatal HIV counseling and testing are not more likely to report adverse social events. AIDS. 2005;19(6):603–9.PubMedCrossRef
36.
Emusu D, Ivankova N, Jolly P, et al. Experience of sexual violence among women in HIV discordant unions after voluntary HIV counselling and testing: a qualitative critical incident study in Uganda. AIDS Care. 2009;21(11):1363–70.PubMedCrossRef
37.
Were E, Curran K, Delany-Moretlwe S, et al. A prospective study of frequency and correlates of intimate partner violence among African heterosexual HIV serodiscordant couples. AIDS. 2011;25(16):2009–18.PubMedCrossRef
38.
39.
The World Health Organization. Delivering HIV test results and messages for re-testing and counselling in adults. Geneva: WHO; 2010.
40.
• Grabbe KL, Bunnell R. Reframing HIV prevention in sub-Saharan Africa using couple-centered approaches. JAMA. 2010;304(3):346–7. This commentary underscores the importance of couples HIV-1 testing and counseling and a couple-focused approach to HIV-1 prevention in sub-Saharan Africa..PubMedCrossRef
41.
Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Annals of Internal Medicine. 2011;155(4):209–16.PubMed
42.
Cotton D. Life expectancy in Africa: back to the future? Annals of internal medicine. 2011;155(4):265–6.PubMed
43.
Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092–8.PubMedCrossRef
44.
Sullivan P, Kayitenkore K, Chomba E, et al. Is the reduction of HIV transmission risk while prescribed antiretroviral therapy (ARVT) different for men and women? Results from discordant couples in Rwanda and Zambia. V International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa; July 19–22, 2009.
45.
Reynolds SJ, Makumbi F, Nakigozi G, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS. 2011;25(4):473–7.PubMedCrossRef
46.
Bunnell R. HIV prevention for a threatened continent: implementing positive prevention in Africa. JAMA: The Journal of the American Medical Association. 2006;296(7):855–8.CrossRef
47.
• El-Sadr WM, Coburn BJ, Blower S. Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS. 2011;25(18):2295–9. A mathematical model estimated the impact of ART initiation on HIV-1 incidence in HIV-1 serodiscordant couples in four African countries. HIV-1 incidence reduction and number of infections averted varied by the proportion of the population in stable partnerships, the percentage of serodiscordant couples, and HIV-1 prevalence..PubMedCrossRef
48.
Hughes JP, Hudelson S, Redd A, et al. Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network (HPTN) 052 trial. VI International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy; July17–20, 2011.
49.
• Guthrie BL, Choi RY, Liu AY, et al. Barriers to antiretroviral initiation in HIV-1-discordant couples. J Acquir Immune Defic Syndr. 2011;58(3):e87–93. A cohort study of HIV-1 serodiscordant couples in Kenya evaluated time to ART initiation in HIV-1-infected partners eligible for free treatment. Socioeconomic status and CD4 count were associated with delayed ART initiation..PubMedCrossRef
50.
Unge C, Johansson A, Zachariah R, et al. Reasons for unsatisfactory acceptance of antiretroviral treatment in the urban Kibera slum, Kenya. AIDS Care. 2008;20(2):146–9.PubMedCrossRef
51.
Haberer J, Baeten J, Celum C, et al. Near perfect early adherence to antiretroviral PrEP against HIV infection among HIV serodiscordant couples as determined by multiple measures: preliminary data from the partners PrEP study. 18th Conference on Retroviruses and Opportunistic Infections. Boston, USA; February 27–March 2, 2011.
52.
Ware NC, Wyatt MA, Haberer JE, et al. What’s love got to do with it? A theory of adherence to oral antiretroviral pre-exposure prophylaxis (PrEP) for HIV serodiscordant couples. AIDS. 2011;In press.
53.
Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.PubMedCrossRef
54.
Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedCrossRef
55.
Thigpen MC, Kebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. VI International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy; July 17–20, 2011.
56.
57.
Microbicide Trials Network. Microbricide Trials Network statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women [Press release]. 2011. Available at http://​www.​mtnstopshiv.​org/​node/​3909. Accessed December 14, 2011.
58.
Karim SS, Karim QA. Antiretroviral prophylaxis: a defining moment in HIV control. Lancet 2011. Epub date: July 21, 2011.
59.
Kim SC, Becker S, Dieffenbach C, et al. Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc. 2010;13:24.PubMedCrossRef
60.
Underhill K, Operario D, Mimiaga MJ, et al. Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep. 2010;7(4):210–9.PubMedCrossRef
61.
Underhill K, Operario D, Skeer M, et al. Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. J Acquir Immune Defic Syndr. 2010;55(1):8–13.PubMedCrossRef
62.
Paxton LA, Hope T, Jaffe HW. Pre-exposure prophylaxis for HIV infection: what if it works? Lancet. 2007;370(9581):89–93.PubMedCrossRef
63.
• Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: A modelling study. PLoS Med. 2011;8(11). This mathematical model examined the cost-effectiveness of PrEP use before ART initiation, the relative cost-effectiveness of PrEP and early ART at various levels of PrEP efficacy and HIV-1 risk behavior, and optimal timing for combining PrEP and ART in HIV-1 serodiscordant couples. The model indicates that at moderate-high PrEP efficacy (>45%) and high ART efficacy (>90%), PrEP may be cost-effective until the HIV-1-infected partner begins ART (CD4 350 in the model) if high-risk couples can be targeted and PrEP delivered cost-effectively.
64.
Nattabi B, Li J, Thompson SC, et al. A systematic review of factors influencing fertility desires and intentions among people living with HIV/AIDS: implications for policy and service delivery. AIDS Behav. 2009;13(5):949–68.PubMedCrossRef
65.
Cooper D, Moodley J, Zweigenthal V, et al. Fertility intentions and reproductive health care needs of people living with HIV in Cape Town, South Africa: implications for integrating reproductive health and HIV care services. AIDS Behav. 2009;13 Suppl 1:38–46.PubMedCrossRef
66.
Myer L, Morroni C, Rebe K. Prevalence and determinants of fertility intentions of HIV-infected women and men receiving antiretroviral therapy in South Africa. AIDS Patient Care STDS. 2007;21(4):278–85.PubMedCrossRef
67.
• Mugo NR, Heffron R, Donnell D, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1 serodiscordant couples. AIDS. 2011;25(15):1887–95. A cohort study with over 3400 HIV-1 serodiscordant couples in Africa found an increased risk of female-to-male and male-to-female HIV-1 transmission during pregnancy..PubMedCrossRef
68.
Beyeza-Kashesya J, Ekstrom AM, Kaharuza F, et al. My partner wants a child: a cross-sectional study of the determinants of the desire for children among mutually disclosed sero-discordant couples receiving care in Uganda. BMC Public Health. 2010;10:247.PubMedCrossRef
69.
Laher F, Todd CS, Stibich MA, et al. A qualitative assessment of decisions affecting contraceptive utilization and fertility intentions among HIV-positive women in Soweto, South Africa. AIDS Behav. 2009;13 Suppl 1:47–54.PubMedCrossRef
70.
Heffron R, Were E, Celum C, et al. A prospective study of contraceptive use among African women in HIV-1 serodiscordant partnerships. Sexually Transmitted Diseases. 2010;37(10):621–8.PubMed
71.
Guthrie BL, Choi RY, Bosire R, et al. Predicting pregnancy in HIV-1-discordant couples. AIDS and Behavior. 2010;14(5):1066–71.PubMedCrossRef
72.
Grabbe K, Stephenson R, Vwalika B, et al. Knowledge, use, and concerns about contraceptive methods among sero-discordant couples in Rwanda and Zambia. Journal of Women’s Health. 2009;18(9):1449–56.PubMedCrossRef
73.
Gruskin S, Ferguson L, Omalley J. Ensuring sexual and reproductive health for people living with HIV: an overview of key human rights, policy and health systems issues. Reproductive Health Matters. 2007;15(29):4–26.PubMedCrossRef
74.
Gruskin S, Firestone R, Maccarthy S, et al. HIV and pregnancy intentions: do services adequately respond to women’s needs? Am J Public Health. 2008;98(10):1746–50.PubMedCrossRef
75.
Ngure K, Heffron R, Mugo N, et al. Successful increase in contraceptive uptake among Kenyan HIV-1-serodiscordant couples enrolled in an HIV-1 prevention trial. AIDS. 2009;23 Suppl 1:S89–95.PubMedCrossRef
76.
• Heffron R, Donnell D, Rees H et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2011. Epub date: October 3, 2011. This observational analysis of 3790 African HIV-1 serodiscordant couples found a twofold increased risk of male-to-female and female-to-male HIV-1 transmission during periods of hormonal contraceptive use. Most women were using injectable progestins.
77.
Matthews LT, Mukherjee JS. Strategies for harm reduction among HIV-affected couples who want to conceive. AIDS Behav. 2009;13 Suppl 1:5–11.PubMedCrossRef
78.
Barreiro P, Castilla JA, Labarga P, et al. Is natural conception a valid option for HIV-serodiscordant couples? Hum Reprod. 2007;22(9):2353–8.PubMedCrossRef
79.
Barreiro P, del Romero J, Leal M, et al. Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;43(3):324–6.PubMedCrossRef
80.
Vernazza PL, Graf I, Sonnenberg-Schwan U, et al. Pre-exposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child. AIDS. 2011;25(16):2049–51.CrossRef
81.
Matthews LT, Baeten JM, Celum C, et al. Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS. 2010;24(13):1975–82.PubMedCrossRef
82.
Hughes JP, Baeten JM, Lingappa JR, et al. Determinants of per coital act HIV-1 infectivity among HIV-1 serodiscordant couples. J Infect Dis. 2011;In press.
83.
Allen C, Mbonye M, Seeley J, et al. ABC for people with HIV: responses to sexual behaviour recommendations among people receiving antiretroviral therapy in Jinja, Uganda. Cult Health Sex. 2011;13(5):529–43.PubMedCrossRef
84.
Rispel LC, Metcalf CA, Moody K, et al. Sexual relations and childbearing decisions of HIV-discordant couples: an exploratory study in South Africa and Tanzania. Reproductive Health Matters. 2011;19(37):184–93.PubMedCrossRef
85.
Coldiron ME, Stephenson R, Chomba E, et al. The relationship between alcohol consumption and unprotected sex among known HIV-discordant couples in Rwanda and Zambia. AIDS and Behavior. 2007;12(4):594–603.PubMedCrossRef
86.
Sarna A, Chersich M, Okal J, et al. Changes in sexual risk taking with antiretroviral treatment: influence of context and gender norms in Mombasa, Kenya. Cult Health Sex. 2009;11(8):783–97.PubMedCrossRef
87.
King R, Khana K, Nakayiwa S, et al. ‘Pregnancy comes accidentally—like it did with me’: reproductive decisions among women on ART and their partners in rural Uganda. BMC Public Health. 2011;11(1):530.PubMedCrossRef
88.
Wagner GJ, Holloway I, Ghosh-Dastidar B, et al. Factors associated with condom use among HIV clients in stable relationships with partners at varying risk for HIV in Uganda. AIDS and Behavior. 2010;14(5):1055–65.PubMedCrossRef
89.
Mermin J, Musinguzi J, Opio A, et al. Risk factors for recent HIV infection in Uganda. JAMA. 2008;300(5):540–9.PubMedCrossRef
90.
Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11):e298.PubMedCrossRef
91.
Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369(9562):643–56.PubMedCrossRef
92.
Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562):657–66.PubMedCrossRef
93.
Baeten JM, Celum C, Coates TJ. Male circumcision and HIV risks and benefits for women. Lancet. 2009;374(9685):182–4.PubMedCrossRef
94.
Wawer MJ, Makumbi F, Kigozi G, et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet. 2009;374(9685):229–37.PubMedCrossRef
95.
Mugwanya KK, Whalen C, Celum C, et al. Circumcision of male children for reduction of future risk for HIV: acceptability among HIV serodiscordant couples in Kampala, Uganda. PLoS One. 2011;6(7):e22254.PubMedCrossRef
96.
Mujugira A, Baeten JM, Donnell D, et al. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One. 2011;6(10):e25828.PubMedCrossRef
97.
Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9630):2109–19.PubMedCrossRef
98.
Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med. 2008;358(15):1560–71.PubMedCrossRef
99.
Mugwanya K, Baeten JM, Mugo NR, et al. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial. J Infect Dis. 2011;204(12):1912–7.PubMedCrossRef
100.
Serwadda D, Gray RH, Wawer MJ, et al. The social dynamics of HIV transmission as reflected through discordant couples in rural Uganda. AIDS. 1995;9(7):745–50.PubMedCrossRef
101.
Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921–9.PubMedCrossRef
102.
Gray RH, Kiwanuka N, Quinn TC, et al. Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. Rakai Project Team. AIDS. 2000;14(15):2371–81.PubMedCrossRef
103.
Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One. 2010;5(9):e12598.PubMedCrossRef
104.
Wang L, Ge Z, Luo J, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. Jaids-J Acq Imm Def. 2010;55(2):232–8.CrossRef
Metadata
Title
HIV-1 Prevention for HIV-1 Serodiscordant Couples
Authors
Kathryn Curran
Jared M. Baeten
Thomas J. Coates
Ann Kurth
Nelly R. Mugo
Connie Celum
Publication date
01-06-2012
Publisher
Current Science Inc.
Published in
Current HIV/AIDS Reports / Issue 2/2012
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-012-0114-z

Other articles of this Issue 2/2012

Current HIV/AIDS Reports 2/2012 Go to the issue

Antiretroviral Therapies (A Pozniak, Section Editor)

Eliminating the HIV Reservoir

Antiretroviral Therapies (A Pozniak, Section Editor)

Treating Women with HIV: Is it Different than Treating Men?

Antiretroviral Therapies (A Pozniak, Section Editor)

Antiviral Drugs and the Treatment of Hepatitis C

Antiretroviral Therapies (A Pozniak, Section Editor)

Protease Inhibitor Monotherapy: What Is Its Role?

Antiretroviral Therapies (A Pozniak, Section Editor)

HIV and Inflammation: Mechanisms and Consequences

Antiretroviral Therapies (A Pozniak, Section Editor)

HIV Therapies and the Kidney: Some Good, Some Not So Good?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits